MedTrace Logo

Treatment of Venous Malformation

NCT05586919 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-10-19

No results posted yet for this study

Summary

Vascular malformations are birth defects that happen when different stages of angiogenesis shut down. 44 - 64% of all vascular malformations are venous malformations (VMs). Sclerotherapy is the first treatment line for VMs. It acts by getting rid of the vascular endothelial cells in the lesion. One of the most common and well researched sclerosing agents for VMs is polidocanol, which is a popular counterpart for concentrated ethanol.

Conditions

  • Venous Malformation

Interventions

PROCEDURE

Direct Puncture Repair / Ethanol

Ethanol is an organic compound that will be injected in the venous malformation as a sclerotherapy by Direct Puncture Repair

PROCEDURE

Direct Puncture Repair / Polidocanol

Polidocanol is a sclerosing agent that will be injected in the venous malformation by Direct Puncture Repair

Sponsors & Collaborators

  • Al-Azhar University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Months
Max Age
36 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2021-01-01
Completion
2021-03-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05586919 on ClinicalTrials.gov